Specialties

Cardiology

ACS, heart failure, arrhythmia and ECGs

The Cardiology engine works like a cardiology consult asked a specific question about a patient. It applies the scores the specialty relies on with every input shown, reads an ECG in a fixed order before considering the differential, and checks for the conditions that imitate a cardiac emergency before suggesting antithrombotic or rate-slowing treatment. Its plans give drug choice and dose in the context of renal function, blood pressure and bleeding risk.

Who it is for

  • General physicians and medical registrars managing chest pain, heart failure and arrhythmia on the take
  • Cardiology trainees preparing a plan before discussing a patient with a consultant
  • Hospital doctors in other specialties who need a cardiology opinion on a patient under their care

What it does

  • Acute coronary syndromes

    Applies the universal definition of myocardial infarction and the high-sensitivity troponin pathway with its time points, scores risk with GRACE, and sets out reperfusion timing, antiplatelet and anticoagulant choice against bleeding risk, and secondary prevention.

  • Heart failure therapy, drug by drug

    Defines the phenotype by ejection fraction, congestion and perfusion, finds the precipitant, and orders the starting and titration of guideline-directed therapy with the blood pressure, potassium and renal limits of each drug.

  • Atrial fibrillation decisions

    Judges stability, rate against rhythm control and cardioversion safety by duration, scores stroke risk with CHA2DS2-VASc or CHA2DS2-VA and bleeding risk with HAS-BLED, and chooses an anticoagulant and dose for age, weight and kidney function.

  • Systematic ECG interpretation

    Reads a described or uploaded ECG in order: rate, rhythm, axis, PR, QRS, corrected QT, then ST segments and T waves by territory, looking for posterior infarction, de Winter, Wellens, ST elevation in aVR and the Sgarbossa criteria.

  • Mimics checked before treatment

    Considers aortic dissection and pulmonary embolism before antithrombotics, right ventricular infarction before nitrates, pre-excitation before AV-nodal blockers, and hyperkalaemia, drug toxicity and non-coronary troponin rises before a primary cardiac label.

  • The rest of the specialty

    Also covers syncope, valve disease and when it needs intervention, hypertensive emergencies, the pericardium and cardiomyopathies, and cardiovascular risk, estimated with whichever calculator your hospital uses.

How it works

  1. The clinician enters the presenting problem with its timeline, the ECG as a description or an image, the troponin trend, BNP, renal function and echo findings, and the current cardiac medicines and bleeding risk.
  2. When an ECG is part of the case, the engine reads it systematically and reports it before anything else.
  3. It applies the relevant scores, showing each input, and checks for the mimics and drug hazards that would change treatment.
  4. It retrieves cardiology guidelines, meta-analyses and trials from PubMed and ClinicalTrials.gov, with US product information for the drugs named, and cites them by number.
  5. It writes the differential, the work-up and a management plan with doses adjusted to the patient, typically in under a minute.

What to include

  • Age, sex and the presenting problem with its timeline
  • ECG description or an uploaded ECG image
  • Troponin trend, BNP, renal function and echo findings
  • Current cardiac medications and bleeding risk

Example cases

  • 68F with NSTEMI, troponin 480 then 1,250 ng/L, eGFR 41, on apixaban for AF. Antithrombotic strategy and timing of angiography?
  • HFrEF, EF 28%, on ramipril and bisoprolol, K 5.3, eGFR 44, BP 102/64. How should therapy be optimised?
  • New AF with a ventricular rate of 148, onset about 30 hours ago, haemodynamically stable. Rate or rhythm control, and anticoagulation?

What the report contains

  1. ECG interpretation, when an ECG is part of the case
  2. Differential diagnosis
  3. Recommended work-up
  4. Management plan
  5. Verified references

Limits

  • An ECG is read only from the description or image supplied. A photograph can lose detail, earlier tracings are needed for comparison, and the reading does not replace the clinician's own interpretation or a formal report.
  • It cannot examine the patient, hear a murmur or review echo images; echo and angiography findings are taken from the report text entered.
  • Attached drug labels are US product information. Anticoagulant dose-reduction criteria differ between US and European labels, and local protocols such as catheter laboratory activation take precedence.

Frequently asked questions

How is the CHA2DS2-VASc score calculated?

One point each for congestive heart failure, hypertension, diabetes, vascular disease (previous myocardial infarction, peripheral arterial disease or aortic plaque), age 65 to 74 and female sex; two points each for age 75 or over and previous stroke, transient ischaemic attack or thromboembolism. The maximum is 9. The engine shows each component it counted.

What is the difference between CHA2DS2-VASc and CHA2DS2-VA?

CHA2DS2-VA is the same score without the point for female sex, so the maximum is 8. The 2024 ESC atrial fibrillation guideline adopted it because female sex adds risk mainly in the presence of other factors. US guidance still uses CHA2DS2-VASc and sets its anticoagulation thresholds for women one point higher, so the two approaches reach similar decisions from different numbers.

Can AI interpret an ECG?

The engine reads an ECG that is described in text or uploaded as an image, in a fixed order, and flags patterns that are easy to miss such as posterior infarction or Wellens syndrome. It supports the clinician's reading and does not replace it or a formal report. A clear, complete image with the calibration and lead labels visible gives the most useful reading.

In what order should heart failure medicines be started in HFrEF?

Current guidelines recommend four classes for heart failure with reduced ejection fraction: an ACE inhibitor, ARB or sacubitril-valsartan, a beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor, started early and close together rather than one at a time over months. The order is individualised by blood pressure, heart rate, potassium and renal function.